Retatrutide Powder
Peptide purity: 98%
Detection method: HPLC
Water solubility: soluble in water
CAS No.: 2381089-83-2
Molecular weight: 4731.33
Molecular formula: C221H342N46O68
Shipping speed:1-3 days
Certificates:HACCP, HALAL, KOSHER, ISO9001, ISO22000, FDA
MOQ:25KG
Sales group:not for individual customers
- Fast Delievery
- Quality Assurance
- 24/7 Customer Service
Product Introduction
What is Retatrutide Powder?
Retatrutide Powder is an active compound called Retatrutide released in June 2023. It is a triple (GLP-1/GIP/Gcg) agonist based on the GLP/GI dual receptor agonist Tirzepatide through a hybrid glucagon (GlucagonGcg) related structure, and is a developed drug for the treatment of obesity and type 2 diabetes. This active compound can activate receptor agonists in our body, which helps control blood sugar and weight loss management.
The third position of the Retatrutide peptide chain is a glycine (G) residue, and the 13th position is a non-natural amino acid aMeL (a-methyl-L-leucine) residue. The use of non-natural amino acid aMeL enhances the activity of the peptide chain for GIP and glucagon receptors. The 17th position is a lysine (K) residue, and a dibasic fatty acid side chain is introduced to this residue through AEEA and y-glutamic acid (yGlu) linkers to achieve a prolonged action time in the body. At position 20 of the Retatrutide peptide chain, an unnatural amino acid Aib is used to prevent the peptide chain from being degraded by dipeptidyl peptidase 4 (DDP4) at this position. Positions 24 and 28 of the peptide chain are optimized to glutamic acid (E) residues, and position 25 is optimized to tyrosine (Y) residues.
Test Report
|
TEST |
SPECIFICATION |
RESULT |
|
Appearance |
White or almost white powder |
Conform |
|
Solubility |
Soluble in water |
Conform |
|
Water Content (Karl Fischer) |
≤8.0% |
6.1% |
|
Sodium salt |
≤5.0% |
3.5% |
|
Peptide Purity (By HPLC) |
≥98.0% |
99.3% |
|
Related Substance (By HPLC) |
Total Impurities(%)≤2.0% |
0.7% |
|
Largest Single Impurity(%)≤1.0% |
0.2% |
|
|
Peptide content |
≥85.0% |
90.3% |
|
Organic solvent residue
|
Acetonitrile≤0.041% |
<0.041% |
|
Dichloromethane≤0.060% |
<0.060% |
|
|
N,N-Dimethylformamide≤0.088% |
<0.088% |
|
|
Bacterial endotoxin |
≤10EU/mg |
<10EU/mg |
|
Conclusion:the product conforms with enterprise standard and qualified |
||
Experiment on weight loss with Retatrutide
Generally speaking, weight loss drugs of the glucagon-like peptide-1 receptor agonist (GLP-1A) type, represented by liraglutide injection and semaglutide injection, can reduce body weight by about 8% or 17% during a one-year follow-up period, while the weight loss effect of current bariatric surgery (gastric volume reduction surgery) is also about 30%. The recently launched Retatrutide is a combined agonist of three hormone receptors, namely, the glucagon-like peptide-1 receptor (GLP-1), the glucose-dependent insulinotropic polypeptide receptor (GIP), and the glucagon receptor (GCG). Can this drug bring more obvious weight loss effects? Recently, the NEJM magazine published the results of the Retatrutide Phase II clinical study.
In this phase 2, randomized, controlled, double-blind clinical trial, the researchers enrolled patients with a body mass index (BMI) >= 30 or BMI >= 27 plus at least one obesity-related disease/abnormality. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous weekly injections of retaglutide (1 mg, 4 mg [initial 2 mg], 4 mg [initial 4 mg], 8 mg [initial 2 mg], 8 mg [initial 4 mg], or 12 mg [initial 2 mg]) or placebo for 48 weeks. The primary endpoint was the percentage change in body weight from baseline at 24 weeks. Secondary endpoints included the percentage change in body weight from baseline to 48 weeks, a weight loss of 5% or more, 10% or more, or 15% or more. Drug safety indicators were also evaluated.
The results showed that of the 338 adults recruited, 51.8% were male. The percentage change in body weight at 24 weeks in the retaglutide group was -7.2% in the 1mg group, -12.9% in the combined 4mg group, -17.3% in the combined 8mg group, and -17.5% in the 12mg group, while it was -1.6% in the placebo group. At 48 weeks of follow-up, the percentage change in body weight in the retaglutide group was -8.7% in the 1 mg group, -17.1% in the combined 4 mg group, -22.8% in the combined 8 mg group, -24.2% in the 12 mg group, and -2.1% in the placebo group. At 48 weeks, the proportion of patients who lost more than 5%, more than 10%, and more than 15% of their body weight was 92%, 75%, and 60% in the 4 mg retaglutide group, 100%, 91%, and 75% in the 8 mg retaglutide group, 100%, 93%, and 83% in the 12 mg retaglutide group, and 27%, 9%, and 2% in the placebo group. The most common adverse reactions in the retaglutide group were gastrointestinal symptoms, which occurred in a dose-related manner, were mostly mild to moderate in severity, and were less common in the group starting with low doses such as 2 mg and 4 mg. Heart rate increased in a dose-dependent manner and declined after reaching a peak at 24 weeks.
Retatrutide Powder supplier
Yuantai Organic Bio is committed to providing customers with the highest-quality Retatrutide Powder 98%and services so that every consumer can enjoy natural, healthy, and high-quality food. If you have any inquiries or needs about our products, please feel free to contact us, and we will reply to you as soon as possible.
Package & Shipment
Our Company and Factory
